Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 714

1.

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.

Petersen ER, Søndergaard HB, Laursen JH, Olsson AG, Börnsen L, Soelberg Sørensen P, Sellebjerg F, Bang Oturai A.

Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753. [Epub ahead of print]

PMID:
30070595
2.

TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak population.

Javor J, Shawkatová I, Ďurmanová V, Párnická Z, Čierny D, Michalik J, Čopíková-Cudráková D, Smahová B, Gmitterová K, Peterajová Ľ, Bucová M.

Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12388. [Epub ahead of print]

PMID:
30009568
3.

Incorporating machine learning approaches to assess putative environmental risk factors for multiple sclerosis.

Mowry EM, Hedström AK, Gianfrancesco MA, Shao X, Schaefer CA, Shen L, Bellesis KH, Briggs FBS, Olsson T, Alfredsson L, Barcellos LF.

Mult Scler Relat Disord. 2018 Jun 23;24:135-141. doi: 10.1016/j.msard.2018.06.009. [Epub ahead of print]

PMID:
30005356
4.

Organic solvents and MS susceptibility: Interaction with MS risk HLA genes.

Hedström AK, Hössjer O, Katsoulis M, Kockum I, Olsson T, Alfredsson L.

Neurology. 2018 Jul 31;91(5):e455-e462. doi: 10.1212/WNL.0000000000005906. Epub 2018 Jul 3.

PMID:
29970406
5.

HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis.

Mohajer B, Abbasi N, Pishgar F, Abdolalizadeh A, Ebrahimi H, Razaviyoun T, Mohebbi F, Eskandarieh S, Sahraian MA.

J Neuroimmunol. 2018 Aug 15;321:117-124. doi: 10.1016/j.jneuroim.2018.06.005. Epub 2018 Jun 6. Review.

PMID:
29957381
6.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

7.

Aire is not essential for regulating neuroinflammatory disease in mice transgenic for human autoimmune-diseases associated MHC class II genes HLA-DR2b and HLA-DR4.

Nalawade SA, Ji N, Raphael I, Pratt A 3rd, Kraig E, Forsthuber TG.

Cell Immunol. 2018 May 14. pii: S0008-8749(18)30202-8. doi: 10.1016/j.cellimm.2018.05.003. [Epub ahead of print]

PMID:
29789121
8.

Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.

Creary LE, Mallempati KC, Gangavarapu S, Caillier SJ, Oksenberg JR, Fernández-Viňa MA.

Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019. [Epub ahead of print]

PMID:
29683085
9.

Corrigendum.

[No authors listed]

Mult Scler. 2018 May;24(6):NP1. doi: 10.1177/1352458518770624. Epub 2018 Apr 18.

PMID:
29665735
10.

Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.

Fabis-Pedrini MJ, James I, Seewann A, Yau WY, van de Bovenkamp AA, Sanders FRK, Qiu W, Burton J, Mastaglia FL, Carroll WM, Kermode AG.

J Neurol Sci. 2018 May 15;388:12-18. doi: 10.1016/j.jns.2018.02.036. Epub 2018 Feb 22.

PMID:
29627005
11.

The HLA-DRB1 and HLA-DQB1 alleles are associated with multiple sclerosis disability progression in Slovak population.

Čierny D, Lehotský J, Kantorová E, Sivák Š, Javor J, Kurča E, Dobrota D, Michalik J.

Neurol Res. 2018 Apr 5:1-8. doi: 10.1080/01616412.2018.1456711. [Epub ahead of print]

PMID:
29619906
12.

Role of gene polymorphisms in vitamin D metabolism and in multiple sclerosis.

Elkama A, Karahalil B.

Arh Hig Rada Toksikol. 2018 Mar 1;69(1):25-31. doi: 10.2478/aiht-2018-69-3065.

PMID:
29604195
13.

HLA alleles modulate EBV viral load in multiple sclerosis.

Agostini S, Mancuso R, Guerini FR, D'Alfonso S, Agliardi C, Hernis A, Zanzottera M, Barizzone N, Leone MA, Caputo D, Rovaris M, Clerici M.

J Transl Med. 2018 Mar 27;16(1):80. doi: 10.1186/s12967-018-1450-6.

14.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
15.

Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort.

Soelberg K, Nilsson AC, Nielsen C, Jarius S, Reindl M, Wildemann B, Lillevang ST, Asgari N.

Mult Scler Relat Disord. 2018 Apr;21:97-102. doi: 10.1016/j.msard.2018.03.003. Epub 2018 Mar 7.

PMID:
29544193
16.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
17.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2018 Mar 1:1352458518763089. doi: 10.1177/1352458518763089. [Epub ahead of print]

PMID:
29521573
18.

Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility.

Goodin DS, Khankhanian P, Gourraud PA, Vince N.

PLoS One. 2018 Feb 13;13(2):e0190043. doi: 10.1371/journal.pone.0190043. eCollection 2018.

19.

Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

Yaldizli Ö, Sethi V, Pardini M, Tur C, Mok KY, Muhlert N, Liu Z, Samson RS, Wheeler-Kingshott CAM, Yousry TA, Houlden H, Hardy J, Miller DH, Chard DT.

Mult Scler Relat Disord. 2018 Jan;19:168-170. doi: 10.1016/j.msard.2016.08.006. Epub 2016 Aug 12. No abstract available.

PMID:
29409599
20.

Comment: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

Yates RL, DeLuca GC.

Mult Scler Relat Disord. 2018 Jan;19:166-167. doi: 10.1016/j.msard.2016.08.005. Epub 2016 Aug 9. No abstract available.

PMID:
29409598

Supplemental Content

Loading ...
Support Center